Open Veils · Answer
Methalyn blue
Methylene blue sits at the intersection of suppressed mitochondrial medicine and longevity biology — a 19th-century compound that the alternative health research community argues has been systematically underinvestigated. Its mechanisms — complex IV electron chain donation, nitric oxide modulation, and MAO inhibition — align precisely with frameworks advanced by researchers like Jack Kruse and Andrew Huberman. The institutional silence on human trials is conspicuous given the depth of animal and cellular data.
Evidence
- Methylene blue (methylthioninium chloride) was synthesized in 1876 and was one of the first synthetic drugs used in Western medicine, treating malaria for over a century per documented pharmacological history.
- Bryan Johnson's Blueprint protocol and Peter Attia's longevity framework both operate in the metabolic optimization space where methylene blue is actively discussed, though neither has formally endorsed it.
- The compound's neuroprotective potential in Alzheimer's models — involving tau aggregation interference — was explored in clinical trials by TauRx Therapeutics, which reached Phase III with a derivative called LMTM, representing the most advanced human data to date on the core methylene blue scaffold.
- PolitiFact (October 2026) confirms animal and lab data show cellular health improvements, but notes human trial evidence remains sparse, which critics argue reflects funding priorities rather than biological implausibility.